The next generation of Apple’s CarPlay interface has been previewed in luxury cars made by Porsche and Aston Martin. The interface, which was first announced more than a year ago at Apple’s WWDC in 2022, is expected to be released next year in select models from the luxury automakers. It builds on previous versions of CarPlay, but will notably connect with all displays in a vehicle instead of just the central infotainment screen, according to Car and Driver.

With each manufacturer partnership, there will be some matching and customization options throughout the screens. For example, the background wallpapers and knobs can mimic a car brand’s style or look. Users will be able to personalize the widgets and apps that appear on the screen, mirroring the form and functions on Apple devices. The CarPlay display will show other key elements like the speed of the car, fuel and temperature on the instrument cluster.

While Porsche and Aston Martin are the first luxury carmakers to tease their collaborations with Apple for branded CarPlay systems, there are no timing specifics regarding the launch of the tool in any specific Porsche models. Aston Martin did share that it will debut CarPlay displays on the DB12 coupe and DB12 convertible in 2024 when they go on sale. Considering Porsche is owned by VW Group, we might see a trickle-down of the latest CarPlay features into VW and Audi models down the road.

Samsung has added a new medication tracking feature to its Health app and it's expected to launch in the US when the app updates later this week. Using the new feature, you can set up alerts to remind yourself when to take medications and get reminders for when to request refills from your doctor.

When you enter a new medication into the app, you can log the shape and color of the pill, information about your prescribed dosage and the time you are scheduled to take the medication. The tool, which competes with the likes of GoodRx and Apple’s Medication app, will give you an overview of a drug’s use and possible side effects, including warnings about potential contraindications. Samsung says the information found within the app is backed by evidence-based content licensed from Elsevier, a publishing company that specializes in medical content.

To start using the new medication tracking tool when it launches, you need a smartphone with at least Android 8.0 and your Samsung Health app version needs to be updated to version 6.26 or later. The feature’s availability also might vary by device.

2023 was an important year for patients with sickle cell disease. Prior to CRISPR, the only cure for the life-long ailment was a bone marrow transplant, which is notoriously dangerous and costly. This month, the FDA approved Vertex’s “Casgevy,” a CRISPR-based therapy for the treatment of sickle cell disease in patients 12 and older. The landmark approval made the therapeutic the first genetically edited therapy to reach the general market.

Casgevy, which also received the greenlight from regulators in the UK for another blood disorder called beta thalassemia, works by being administered in a single-infusion of genetically modified stem cells to a patient. Clinical study participants that took Casgevy were free from symptoms associated with sickle cell disease, like periodic episodes of extreme pain due to blocked blood flow through vessels, for up to a year.

CRISPR, which modifies precise regions of a human’s DNA strands, was once thought to be a far off scientific innovation. Human cells were first modified using CRISPR in clinical trials in China back in 2016. Less than a decade later, these landmark approvals have set the stage for future nods by regulators for other CRISPR-based therapies that can treat things like HIV, cancers and high blood pressure. “Gene therapy holds the promise of delivering more targeted and effective treatments,” Nicole Verdun, director of the Office of Therapeutic Products within the FDA’s Center for Biologics Evaluation and Research said in a recent press release.

ASSOCIATED PRESS

CRISPR-based gene editing can be designed as a therapeutic for a number of diseases. A scientist can either delete, disrupt or insert segments of DNA to treat conditions by either targeting specific genes or engineering new cell therapies. The editing process can occur ex vivo (outside the body), in the same way Casgevy does, or in vivo (inside the body). Using CRISPR, sickle cell patients’ blood stem cells are modified in a lab before they are re-infused via a single-dose infusion as part of a hematopoietic transplant.

Neville Sanjana, a core faculty member at the New York Genome Center and associate professor in the Department of Biology at New York University, runs the Sanjana lab, which develops gene therapies for complex diseases like autism and cancer. “One of the really fundamental characteristics of CRISPR is its programmability,” Sanjana told Engadget. While working at the Zhang lab at the Broad Institute of MIT and Harvard, Sanjana says he helped design the “guide RNA” that became the blueprint for Vertex’s Casgevy. “CRISPR screens can be powerful tools for understanding any disease or genetic trait,” Sanjana said. Right now, he said biomedical folks are focused on applying CRISPR-based therapies for really serious inheritable diseases.

While it does “set a precedent” to have these first CRISPR-based gene therapies out there, it could also mean that regulators and the general public will regard future innovations in the space as “less novel,” Katie Hasson, a researcher with the Center for Genetics and Society (CGS) told Engadget. The CGS is a public interest and social justice organization that is focused on making sure gene editing is developed and distributed for good. Hasson explained, it doesn't mean that because one got approved that all other innovative therapies to come after it will not get as much scrutiny.

Beyond therapeutics, gene editing has very broad applications for the discovery and understanding of diseases. Scientists can use CRISPR to explore the origins of things like cancer and pave paths for therapeutics and incurable diagnoses, but that's not all there is to it. Scientists still need to conduct “considerable experimental research” when it comes to bringing an actual therapeutic to fruition, Sanjana said. “When we focus on therapeutic activity at a particular site in the genome, we need to make sure that there will not be any unintended consequences in other parts of the genome.”

Still, the spotlight will always shine a brighter light on the flashy developments of CRISPR from a therapeutic standpoint. Currently, a new gene editing method is being developed to target specific cells in a process called “cancer shredding“ for difficult-to-treat brain cancer. Scientists have even discovered a pathway to engineer bacteria to discover tumorous cells. However, there are barriers to using CRISPR in clinical practice due to the lack of “safe delivery systems to target the tissues and cells.”

“Maybe by curing one disease, you might give them a different disease — especially if you think of cancer. We call that a secondary malignancy,” Sanjana said. While there is strong reason for concern, one cure creating a pathway for other diseases or cancers is not unique to CRISPR. For example, CAR T cell therapy, which uses an entirely different approach to cell-based gene therapy and is not reflective of CRISPR, is a lifesaving cancer treatment that the FDA discovered can, in certain situations, cause cancer.

“We definitely don't want any unintended consequences. There are bits of the genome that if you edit them by mistake, it's probably no big deal but then there are other genes that are vitally important,” Sanjana said. Direct assessment of “off-target effects” or events in which a gene edit incorrectly edits another point on a DNA strand in vivo is challenging.

The FDA recommends that after a clinical trials’ period of investigatory study looking at the efficacy of a gene editing-based therapy, there needs to be a 15-year long term follow up after product administration. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, said that the agency’s approval of Casgevy follows “rigorous evaluations of the scientific and clinical data.” Right now, researchers are focused on improving the precision and accuracy of gene editing and having the proper follow up is absolutely well merited, Sanjana explained. “The process right now is a careful one.”

Hasson believes that the 15-year recommendation is a good start. “I know that there is a big problem overall with pharmaceutical companies actually following through and doing those long term post-market studies.”

That’s where new approaches come into play. Base editing, a CRISPR-derived genome editing method that makes targeted changes to DNA sequences, has been around since 2016. Drugs that use base editing have already made headway in the scientific community. Verve Therapeutics developed a gene edited therapy that can lower cholesterol in patients with a single infusion. At higher doses, Verve said the treatment has the potential to reduce proteins associated with bad cholesterol for 2.5 years. Base editing, like CRISPR, has many potential applications for treatment and discovery. For example, base editing could repair a gene mutation that causes childhood blindness. Researchers at Weill Cornell Medicine also found base editing could help understand what genetic changes influence a patient’s response to cancer therapies.

Base editors use CRISPR to bring another functional element to a specific place in the genome. “But it doesn't matter whether it's CRISPR cutting or base editing… any time you're modifying DNA…you would want to know what the off target effects are and you can bet that the FDA wants to know that too. You're going to need to collect data using standard models like cell culture, or animal models to show there are zero or near zero off-target impacts,” Sanjana said.

CRISPR-based therapies already show high therapeutic potential for conditions beyond sickle cell disease. From blood based treatments, to edited allogeneic immune cells for cancers, there are a number of human clinical trials underway or expected to start next year. Trials for gene-edited therapies that target certain cells for cancer and autoimmune diseases are expected to begin in 2024.

Boston Globe via Getty Images

It won't be until 2025 before we get a better understanding of how Excision BioTherapeutics’ CRISPR-based therapy works to treat HIV. The application of gene editing as a therapeutic for Alzhiemer’s is still in the early stages, with mice at the forefront of research. Similarly, University College London researchers proved that CRISPR has promise as a potential therapeutic for treatment-resistant forms of childhood epilepsy. In a recent study, a gene edited therapy developed in the lab was shown to reduce seizures in mice.

But the clinical process of getting CRISPR to safely and effectively work as it's intended isn’t the only hurdle. The pricing of CRISPR and related therapies in general will be a huge barrier to access. The Innovative Genomics Institute (IGI), a research group that hopes to advance ethical use of these gene editing in medicine, estimates that the average CRISPR-based therapy can cost between $500,000 and $2 million per patient. The IGI has built out an “Affordability Task Force” to tackle the issue of expanding access to these novel therapies. Vertex’s sickle cell treatment costs a cool $2.2 million per treatment, before hospital costs. David Altshuler, the chief scientific officer at Vertex, told MIT Tech Review that wants to innovate the delivery of the therapeutic and make it more accessible to patients. “I think the goal will be achieved sooner by finding another modality, like a pill that can be distributed much more effectively,” Altshuler said.

“Access is a huge issue and it's a huge equity issue,” the CGS’ Hasson told Engadget. “I think we would also like to look at equity here even more broadly. It's not just about who gets access to the medication once it comes on the market but really how can we prioritize equity in the research that's leading to these treatments.” The US already does a poor job of providing equitable healthcare access as it is, Hasson explained, which is why it's important for organizations like CGS to pose roundtable discussions about implementing guardrails that value ethical considerations. “If you support people having access to healthcare, it should encompass these cutting edge treatments as well.”

The National Labor Relations Board (NLRB) has found that eBay has violated the rights of unionized workers at TCGPlayer, a trading card marketplace owned by the company. This comes in response to charges filed by the Communications Workers of America back in March of this year. eBay has allegedly refused to recognize TCGPlayer’s worker union and it delayed participating in any bargaining practices and it has also refused to divulge any information with the group that the union is legally entitled to.

As part of its examination of the issue, the NLRB said that because eBay and TCGPlayer broke the law, the company must face legal consequences for its union-busting practices. The union, which officially formed in March following numerous anti-union actions from eBay and TCGPlayer, was denied representation during disciplinary investigations. The NLRB also found that eBay was changing working conditions and benefits without engaging in bargaining with the group. On top of that, eBay is said to have even enforced rules that would punish any workers’ elections to unionize.

While the NLRB lays out evidence of eBay’s union-busting practices, it did not officially issue a decision on the matter. The agency is still waiting on the company’s response to the issue. “Now that the board has come to a decision on eBay’s illegal practices, we hope the company will see the light, obey labor law and engage in good faith bargaining practices so that workers can secure a strong union contract,” Dennis Trainor, Communications Workers of America District 1 Vice-President, said in a statement. eBay could not be reached for comment.

Galaxy Z Flip 5 and Z Fold 5 owners can now fix their phones through Samsung's self-repair service. The do-it-yourself program is expanding so that more Galaxy products, including foldables and tablets, are included in the iFixit collaboration. 

Samsung said it will add seven more products this month to its list of devices that are eligible for self-repair – from PCs, smartphones and tablets — including the Galaxy S23 series, Tab S9 series and the Galaxy Book2 Pro series. The program provides users with original equipment manufacturer (OEM) device parts and step-by-step guides that allow for things like screen or battery replacements. The price of fix kits will vary depending on the device. For example, a Samsung Galaxy S22 Ultra Screen and Battery set costs $240.

Samsung’s self-repair program, which first launched in the US last year, will also be offered to customers in an additional 30 countries across Europe. The company says expanding the scope of what’s covered by the program is in line with Samsung’s overall strategy to alleviate e-waste.

Google is giving anyone who has a WiFi-only Stadia controller lying around an additional year to convert it to Bluetooth. The deadline to do this was previously until the end of this year, but Google is now extending it to December 31, 2024.

Google axed Stadia, its cloud gaming service, at the beginning of this year. Most customers who bought digital games through the Google Store got refunds, but some physical hardware such as Stadia’s controller that connected directly to WiFi, is still out there. Enabling Bluetooth on Stadia controllers will let people use them with any other devices such as PCs, Macs, phones or tablets. This, as Kotaku points out, could prevent e-waste.

Switching your controller to Bluetooth is permanent. It takes about three minutes and requires a USB cable, according to Google. To pair a Stadia controller to Bluetooth, you need to press and hold the Y and Stadia button for at least two seconds. You’ll know that the controller has entered “pairing mode” when the status light flashes orange. If you’re having issues establishing a connection, Google advises making sure that the controller is charged for at least 30 minutes.

You can now mindlessly scroll your TikTok’s ‘for you page’ on larger screens and foldable devices. The new update will be available for users worldwide and on devices like the iPad or the various foldable Android phones out there. TikTok, which is traditionally mobile-forward, said it will deliver a clear video feed of content on bigger screens with “enhanced clarity.”

The top and bottom of screens that stream TikTok videos will have a navigation bar that makes it easier to access tabs and featured videos. With this update, clips can also be watched in landscape orientation. This creates new opportunities for video creators to generate content in a horizontal format after years of a vertical-only.

TikTok also said it is going to continue experimenting with features like Topic Feeds, which would allow users to explore videos in specific categories like gaming, food or fashion. The platform has been exploring new ways to deliver content to users and it has been quietly testing the idea of an AI-powered chatbot that can recommend videos to users. While it’s still the leading app for short-form videos, creating unique ways to deliver content to its users can help set the social media company itself apart from competitors in the space, like Instagram’s Reels and YouTube Shorts.

If you used Apple’s Family Sharing feature with at least one other person and bought a subscription to an app through the App Store between 2015 and 2019, you might just get a settlement of up to $50 from the company. MacRumors reports that Apple will pay $25 million to settle a class action lawsuit that accuses the tech giant of misleading customers over Family Sharing.

The feature lets up to six family members share app subscriptions with each other but allows individual developers to forbid people from sharing a single subscription if they wish to. The lawsuit, which was filed in 2019, accuses Apple of not being transparent about this and misleading customers by making them think they could share a subscription to every app available in the App Store. “[The] vast majority of subscription-based apps” did support Family Sharing, the lawsuit claims.

The complaint also alleges that Apple placed ads on the landing pages of some subscription-based apps that didn’t support Family Sharing. This led “millions of customers” to download subscription-based apps believing they would be able to access them through their Family Sharing subscription, it says, citing YouTube Red and a puzzle game called Brainwell as examples of apps that didn’t support sharing their subscriptions with family members. 

Apple has reportedly denied any wrongdoing and has only agreed to settle the case to avoid the potential costs associated with a jury trial. The company did not respond to a request for comment from Engadget.

Twitch has quickly taken back its policy update that permitted users to post sexual content as long as it was labeled. In another update, the company said it is not going to allow any depictions of real or fictional nudity on its streaming platform. After giving users the green light to post “artistic nudity,” Twitch says some streamers created content that violated policy.

The media streamed in response to the initial approval of sexually explicit content on Twitch was “met with community concern,” according to the update. The company said, “We have decided that we went too far with this change.”

While a huge part of the initial decision was to allow for the “digital depiction” of artistic nudity, the company clarified that digital depictions of sexual content is a concern when artificial intelligence can be used to develop realistic images and that it can be difficult to discern between what's been digitally produced and real photography.

Recently at TwitchCon in Las Vegas, the company introduced new moderation measures meant to keep inappropriate content out of stream chats. The issue of sexual abuse and inconsistent moderation policies through the site has been a recurring problem for the live-streaming platform. The company even dedicated a Safety Advisory Council in 2020 meant to tackle the site’s bad reputation for its moderation practices.

Twitch’s back and forth stance on the issue of sexually explicit content has enraged some users. @Saruei_, a user on X wrote, “I got banned wrongly under your new policy for drawing a nude character without any visible genitalia. This is your own responsibility for not thinking through before establishing a new TOS and it is incredibly unfair to a lot of artists who fell into the same situation as myself.” Another Twitch user @LuxDenizen took to X to complain, “Sucks for the artists who were actually following all of the rules. THIS IS WHY WE CAN'T HAVE NICE THINGS.”

Meta is rolling out a suite of new tools on Instagram that give users more control over how much spam content and bots they will see on their feeds. People will also be told if something they posted is in accordance with community guidelines. The new tools will be introduced gradually in the coming weeks.

Instagram has developed and improved its automated detection system that checks for spam across comments, tags, story views and followers. The moderation systems will flag fake followers and spam-filled content and give users the option to delete those items in bulk to save users time. Any suspected spam or bot account will get filtered into a separate inbox for you to review, and if an account isn’t spam, you can approve a request and they’ll be added to your following list. Otherwise, all accounts will be automatically removed after 30 days. Posts by profiles that get tagged as spam won't appear on the content creators’ accounts unless they get approved. An account holder can view, bulk delete or approve any tag requests flagged by the system.

Instagram will also send in-app notifications if it detects posts that violate its content policies. This follows Instagram’s most recent update that shows when posts are blocked from appearing on the Explore page, which should stop account holders from repeating those mistakes. For Stories though, Instagram said it is still experimenting with hiding views from accounts that the platform deems as spam.

The company already introduced the "Hidden Words" tool in 2021, which hides messages with questionable keywords. In the coming update, Instagram said it will start to edit out suspected spam through the advanced comment filtering tool. The issue of harassment and spam has long been a focal point for Instagram. It has had to deal with bots storming the platform and proliferating sexually explicit content. However, the company needs to strike a balance between policing inappropriate content and allowing for the free exchange of ideas on its platform. Recently, Instagram has faced scrutiny for allegedly censoring pro-Palestinian content amid the ongoing war in the Gaza.